Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11195250 | 0.84 | POLB (0.61) | ALDH1A1CYP2C9MEN1KMT2APKM | |
| Methane SCHEMBL3417314 | 0.83 | MAPK1 (0.58) | ALDH1A1CYP2C9MEN1KMT2APKM | |
| SCHEMBL2099509 | 0.81 | TP53 (0.52) | ALDH1A1CYP2C9MEN1KMT2AHSD17B10 | |
| SCHEMBL8883167 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP2C9MEN1KMT2AHSD17B10 | |
| SCHEMBL8115003 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP2C9MEN1KMT2AHSD17B10 | |
| SCHEMBL30646274 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP2C9MEN1KMT2AHSD17B10 | |
| SCHEMBL8876086 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP2C9MEN1KMT2AHSD17B10 | |
| SCHEMBL1827394 | 0.79 | ALDH1A1 (0.59) | ALDH1A1CYP2C9MEN1KMT2AHSD17B10 | |
| SCHEMBL3594763 | 0.78 | ALDH1A1 (1.00) | ALDH1A1CYP2C9MEN1KMT2APKM | |
| SCHEMBL10414873 | 0.77 | ALDH1A1 (0.58) | ALDH1A1CYP2C9MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204451-A1 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY, INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-10-14 | — | — | US | claimed |
| US-20040132778-A1 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-07-08 | — | — | US | claimed |
| US-20030139445-A1 | Method for treating retroviral infections | BIOLAB, INC. | 2003-07-24 | — | — | US | claimed |
| WO-2003037311-A2 | METHOD FOR TREATING RETROVIRAL INFECTIONS | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2003-05-08 | — | — | WO | claimed |
| US-7064139-B2 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20040204451-A1 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY, INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-10-14 | — | — | US | disclosed |
| US-20040132778-A1 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-07-08 | — | — | US | disclosed |
| US-20030139445-A1 | Method for treating retroviral infections | BIOLAB, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003037311-A2 | METHOD FOR TREATING RETROVIRAL INFECTIONS | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204451-A1 | Method for treating retroviral infections | TPMT, ALB, GARS1 | ALDH1A1 825/4885CYP2C9 1982/4885MEN1 4024/4885 |
| US-20030139445-A1 | Method for treating retroviral infections | TPMT, ALB, GARS1 | ALDH1A1 825/4885CYP2C9 1982/4885MEN1 4024/4885 |
| US-20040132778-A1 | Method for treating retroviral infections | TPMT, TYMP, ARSA | ALDH1A1 977/4885CYP2C9 2052/4885MEN1 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.